Serotonergic Psychedelics as Antidepressants: What the Evidence Actually Shows
By Dr. Anindo Mitra | MBBS, MD Psychiatry (JIPMER) | Consultant Psychiatrist, Athena Behavioural Health, Gurugram
Published on dranindomitra.com | Reading time: ~12 minutes
TL;DR — Key Takeaways
• Psilocybin has the strongest antidepressant evidence among serotonergic psychedelics, with pooled effects in the moderate-to-large range across multiple RCTs.
• A 2023 paper in the American Journal of Psychiatry found antidepressant effects from psilocybin even when the psychedelic experience was pharmacologically suppressed, suggesting a direct neurobiological mechanism independent of the 'trip.'
• Animal data show psilocybin's antidepressant-like effects persist even in 5-HT2A knockout mice, indicating its mechanism goes beyond classic serotonergic signaling.
• The neuroplasticity model is the strongest convergent mechanism: psychedelics appear to act as rapid plasticity-enhancing agents, promoting dendritic spine growth, synaptogenesis, and BDNF-related signaling.
• Effect sizes in the literature look large partly because many studies use small samples, waitlist controls, and cancer-related distress populations. Larger controlled trials show a more modest but still clinically meaningful signal.
• Psilocybin is not legally available for clinical use in India. I am presenting this evidence because patients deserve accurate information, not because I offer this treatment.
What subjective effects do serotonergic psychedelics produce?
Serotonergic psychedelics produce a characteristic cluster of perceptual, cognitive, and emotional effects that are dose-dependent and compound-specific. These include visual and sensory distortions, a compressed or expanded sense of time, heightened emotional salience (ordinary memories or conversations acquire unusual intensity), and at higher doses, ego dissolution — a disruption of the boundary between self and world that some patients describe as the most significant experience of their lives and others find acutely distressing. These effects are not incidental; they are what makes blinding impossible in clinical trials and what drives much of the expectancy research.
Two validated instruments measure these experiences in research settings. The Ego Dissolution Inventory (EDI) captures the degree to which a participant's sense of self as a distinct entity breaks down during the session. The Mystical Experience Questionnaire (MEQ30) measures qualities including unity, noetic content, transcendence of time and space, and a sense of sacredness. Both scores correlate with antidepressant response in multiple trials, though this correlation is contested — the 2023 American Journal of Psychiatry finding that antidepressant effects occurred even without the subjective experience complicates the picture.
Onset and duration differ meaningfully across compounds:
Psilocybin: onset 20–40 minutes after oral ingestion; full effects typically at 60–90 minutes; duration 4–6 hours. The experience tapers gradually, which most patients find manageable.
LSD: onset 30–60 minutes; duration 8–12 hours. The longer duration creates practical challenges for supervised clinical settings — session days are longer, therapist demands are higher, and the risk of a prolonged difficult experience is extended.
Smoked DMT: onset within seconds to 2–3 minutes; peak at around 5–10 minutes; fully resolved within 20–30 minutes. Duration that brief is both its clinical appeal and its limitation — there is very little time for therapeutic processing within the experience itself.
One practical point for anyone currently on antidepressants: concurrent SSRI use substantially blunts the effects of psilocybin and LSD, likely through 5-HT2A receptor downregulation. This has both safety and efficacy implications, covered in the serotonin syndrome section below.
Psychedelics have re-entered the psychiatric literature at speed. The conversation has moved from fringe to peer-reviewed journals, FDA breakthrough designations, and prime-time news. Within that conversation, a lot of claims get made, and most of them are either overclaimed or dismissed without engagement with the actual data.
This post is an attempt to lay out what the evidence shows, cleanly and honestly. I will cover what serotonergic psychedelics are, how they appear to work, what the clinical trials actually found, why some effect size numbers should be read with caution, and what this means for psychiatry today.
I am writing about psilocybin primarily, because it has the strongest evidence base. Where DMT/ayahuasca and LSD are relevant, I will note them. I am deliberately not including MDMA, whose evidence is stronger in PTSD than in primary depression, and mixing it into a depression-focused discussion would misrepresent what the literature supports.
What Are Serotonergic Psychedelics?
Serotonergic psychedelics are a class of compounds that produce their primary effects through agonism at the serotonin 5-HT2A receptor. The main agents are psilocybin (found in certain mushroom species, converted in the body to psilocin), LSD (lysergic acid diethylamide), and DMT (dimethyltryptamine, the active compound in ayahuasca when taken orally). They are structurally and pharmacologically distinct from MDMA, which acts primarily through monoamine release rather than receptor agonism.
The US FDA designated psilocybin as a Breakthrough Therapy for treatment-resistant depression in 2018, a designation designed to accelerate research. This does not constitute approval for clinical use, but it reflects the seriousness with which regulatory bodies have begun engaging with this evidence base. At present, serotonergic psychedelics are controlled substances in India under the NDPS Act and are not available in any licensed clinical setting in the country.
Compound profiles: psilocybin, LSD, DMT, mescaline, and 5-MeO-DMT
The serotonergic psychedelics are not a single compound. They share 5-HT2A agonism as a primary mechanism but differ substantially in source, onset, duration, and the clinical nuances that matter for research and risk assessment.
Psilocybin is a prodrug found in over 200 mushroom species, converted in the body to its active form psilocin by alkaline phosphatase. Onset: 20–40 minutes. Duration: 4–6 hours. It has the largest and most methodologically robust clinical evidence base of any psychedelic under investigation for depression, including Phase 2b RCT data from COMPASS Pathways (NEJM, 2022) and Raison et al. (JAMA, 2023). Key clinical note: excluded from use in anyone with personal or first-degree family history of psychosis or bipolar I. In India, classified as a controlled substance under the NDPS Act.
LSD (lysergic acid diethylamide) is a semi-synthetic compound derived from ergot alkaloids, first synthesised by Albert Hofmann in 1938. Onset: 30–60 minutes. Duration: 8–12 hours. Depression-specific RCT evidence is thin; anxiety-focused trials show sizeable effects but are not directly transferable. The extended duration creates practical barriers to supervised clinical use. High potency at microgram doses creates a narrow margin between therapeutic and overwhelmingly intense experiences.
DMT (dimethyltryptamine) is structurally a tryptamine, occurring endogenously in human tissue at trace concentrations, though whether endogenous DMT serves any physiological function remains an open question in the literature. Smoked or vaporised: onset in seconds, duration 15–20 minutes. When taken orally in the form of ayahuasca, DMT is combined with beta-carboline MAOIs (from the Banisteriopsis caapi vine), which inhibit monoamine oxidase and allow oral bioavailability. Without this MAOI component, orally ingested DMT is inactivated in the gut before reaching systemic circulation.
DMT's receptor pharmacology is broader than psilocybin's. It acts as a potent 5-HT2A agonist (the shared mechanism), a partial agonist at 5-HT1A, and a sigma-1 receptor agonist. Sigma-1 receptors are intracellular chaperone proteins implicated in neuroprotection, neuroplasticity, and antidepressant biology — and their involvement may help explain why DMT's neurobiological profile differs from psilocybin's despite structural similarities. IV DMT Phase IIa data shows a preliminary antidepressant effect size around d = 0.82, but this is a very early signal.
The ayahuasca-SSRI interaction deserves specific attention. Because ayahuasca contains functional MAOIs, concurrent use with SSRIs or SNRIs carries a genuine, established risk of serotonin syndrome — not a theoretical concern. This is a real contraindication, not a precaution. It is covered in detail in the serotonin syndrome section below.
Mescaline is the active compound in peyote and San Pedro cacti. It has a long history of ceremonial use but very limited modern clinical trial data for depression. Onset: 1–2 hours. Duration: 10–12 hours. Its prolonged duration and relative lack of recent clinical research mean it sits outside the current evidence-based discussion for depression.
5-MeO-DMT (5-methoxy-dimethyltryptamine) is found in several plant species and in the parotoid gland secretions of the Sonoran Desert toad (Incilius alvarius). Its subjective effects are rapid and intense, frequently described as complete ego dissolution at threshold doses. Duration when smoked: 15–30 minutes. Early data in depression and existential distress show preliminary signals, but clinical evidence is very sparse — one prospective observational study (Uthaug et al., 2019) and limited case series. Not comparable to psilocybin in evidence quality.
How Could Psychedelics Work as Antidepressants? The Neurobiology
The classic theory: it is the experience
The initial hypothesis was intuitive: the psychedelic experience, particularly its 'mystical' or 'ego-dissolving' quality, was therapeutically active. Studies showed that the magnitude of the acute mystical experience correlated with antidepressant response. This framing positioned psychedelic therapy as partly a pharmacological catalyst for psychological reorganisation, which is why treatment always involves preparation, the drug session, and post-session integration.
The challenge: antidepressant effects without the trip
A 2023 paper in the American Journal of Psychiatry by Rosenblat, Leon-Carlyle, Ali, Husain, and McIntyre examined whether antidepressant effects required the psychedelic experience at all. The finding: antidepressant effects were observed even in the absence of the subjective psychedelic state. This is clinically significant because it suggests psilocybin has direct neurobiological antidepressant mechanisms that operate independently of its perceptual effects.
Animal data add further weight. A preclinical study compared the hallucinogenic 5-HT2A agonist DOI, psilocybin, and lisuride, a non-hallucinogenic ergot derivative with 5-HT2A agonist properties, in a chronic despair mouse model. All three produced rapid and prolonged antidepressant-like effects lasting up to 15 days. Critically, when DOI and lisuride were tested in 5-HT2A knockout mice, their antidepressant-like effects disappeared. Psilocybin's effects, however, persisted even in those knockout animals, and blocking 5-HT1A, dopamine D1, and D2 receptors did not abolish them. The implication is that psilocybin's antidepressant biology is not fully reducible to 5-HT2A signaling.
The honest summary is this: hallucinogenic experience is probably not universally required for antidepressant biology. Whether it is sometimes clinically synergistic or necessary in certain patients remains an open question.
The receptor-level story: two intracellular pathways
At the receptor level, serotonergic psychedelics engage two distinct intracellular cascades after binding 5-HT2A. The Gq/alphaQ pathway activates phospholipase C, generating calcium mobilisation and inositol phosphates. The beta-arrestin-2 pathway recruits Src kinases and triggers ERK1/2-MAPK signalling, a cascade that is downregulated in the prefrontal cortex and hippocampus in depression. The current evidence suggests that Gq signalling is more closely linked to the psychedelic-like effects in rodents, while beta-arrestin-2 biased signalling may produce antidepressant-like effects without the hallucinogenic component. This distinction is the basis for active research into non-hallucinogenic derivatives of psychedelics.
Neuroplasticity: the strongest convergent mechanism
If there is one neurobiological theme to take from the current literature, it is this: serotonergic psychedelics appear to act as rapid plasticity-enhancing agents.
The evidence across multiple preclinical studies points consistently toward increased dendritic spine density and formation, increased synaptogenesis, elevated BDNF signalling, and recovery of lost dendritic spine density in prefrontal and hippocampal regions. LSD and psilocin have also been shown to bind TrkB, the BDNF receptor, independent of 5-HT2A activation, and TrkB binding induces neuroplasticity and antidepressant-like effects in mice without the head-twitch response associated with psychedelic effects. This makes TrkB/BDNF signalling one of the most compelling candidate mechanisms for durable antidepressant benefit.
This plasticity model fits a broader logic visible in newer rapid-acting antidepressants: a brief pharmacological intervention opens a window of increased neural malleability during which cognition, affect, and behaviour can reorganise more adaptively.
Network-level effects: the default mode network
At the systems neuroscience level, depression is associated with hyperconnectivity within the default mode network (DMN), the brain's resting-state circuit most closely linked to rumination and self-referential thinking. After psilocybin treatment, studies have found decreased DMN connectivity that correlates with symptom improvement. Simultaneously, there appears to be increased connectivity between the DMN and executive and salience networks, potentially restoring reward processing, motivational function, and the ability to switch out of self-focused cognition.
A useful clinical formulation: psychedelics may reduce the brain's tendency to remain trapped in rigid self-referential loops, reopening communication between networks needed for attention switching, emotional salience, and behavioural change. This fits the phenomenology of depressed patients who describe feeling 'stuck.'
Cognitive flexibility
The same literature identifies cognitive flexibility as a central mechanism. Psilocybin has been associated with reduced rumination, reduced thought suppression, improved cognitive function, and a potentially enhanced capacity for social learning. This is probably why psychotherapy is so consistently paired with psychedelic treatment: patients may not just feel less depressed but become temporarily less rigid, less avoidant, and more able to revise entrenched emotional narratives. The drug creates a window; the psychotherapy tries to use it.
What Do the Clinical Trials Actually Show?
Psilocybin in treatment-resistant depression
The most clinically persuasive trial in the current evidence base is Goodwin et al. (2022), published in the New England Journal of Medicine. This was a Phase 2b double-blind, dose-finding RCT across 22 sites and 10 countries, involving 233 adults with treatment-resistant depression (TRD), defined as failure of at least two antidepressants. Participants were randomised to a single dose of 1 mg (control), 10 mg, or 25 mg psilocybin alongside structured psychological support.
At 3 weeks, 37% of patients in the 25 mg group had responded versus 18% in the 1 mg control group. The effect size for 25 mg was g= -0.61 on the MADRS. The 10 mg group was not significantly different from control. At 12 weeks, 20% of the 25 mg group sustained response, compared to 10% in the control arm. These are modest numbers, but in a population that has already failed multiple treatments, a 37% response rate at 3 weeks from a single dose is worth sitting with.
Psilocybin in MDD
Raison et al. (2023), published in JAMA, tested a single 25 mg dose of psilocybin versus niacin placebo in 104 adults with moderate-to-severe MDD across 11 US sites. At day 43, the psilocybin group showed a mean MADRS reduction of 19.1 points versus 6.8 in the niacin group (mean difference -12.3, p<0.001). Effects were evident by day 8. Functional disability (Sheehan Disability Scale) also improved significantly with psilocybin. There were no serious treatment-emergent adverse events, though the psilocybin arm had a higher rate of overall and severe adverse events.
Psilocybin vs escitalopram
Carhart-Harris et al. (2021) compared psilocybin with escitalopram in 59 patients with moderate-to-severe MDD. The primary outcome was not significantly different between arms (d approximately 0.21 on MADRS), but several secondary measures favoured psilocybin. This trial is often cited as evidence that psilocybin 'beats' SSRIs. That is an overstatement. A small underpowered pilot trial raises a hypothesis; it does not confirm one. The study's importance lies partly in showing that the evidence is not uniformly positive on every primary endpoint, which is itself clinically useful information.
Meta-analytic summary
A 2024 meta-analysis in Frontiers in Psychiatry pooled 8 RCTs involving 524 patients and found a large effect size in favour of psilocybin (Hedges' g = -0.89, 95% CI -1.25 to -0.53, I2 = 70%). Other pooled analyses have found effect sizes ranging from approximately g = 0.69 to g = 1.64 depending on the studies included, the comparison condition, and the outcome measure. The heterogeneity is high across all analyses.
DMT/ayahuasca and LSD: where things stan
Ayahuasca has early data suggesting moderate-to-large antidepressant effects, including one RCT described as producing large effects. IV DMT Phase IIa data suggest an effect size around d = 0.82. These are preliminary signals from small samples, not a settled evidence base.
LSD's depression-specific evidence is thin. Anxiety-focused studies show sizeable changes, but it would overstate the current literature to present LSD as having strong antidepressant RCT evidence.
Why Some of These Effect Sizes Should Be Read with Caution
Several features of this literature inflate effect size estimates:
Small sample sizes: several frequently cited studies involve fewer than 30 participants
Waitlist controls: comparison against a waitlist rather than active placebo inflates the apparent treatment effect
Cancer-related distress populations: studies in patients with life-threatening illness and existential distress tend to show larger effects than studies in primary MDD or TRD samples
Functional unblinding: participants almost always know whether they received psilocybin, making true blinding near-impossible and introducing expectancy effects
Bundled psychotherapy: it is very difficult to separate the pharmacological effect of the drug from the intensive psychological support that accompanies it in every trial
The most conservative and defensible interpretation comes from larger controlled trials with active comparators. The Goodwin et al. NEJM trial, the largest and most controlled in the dataset, showed an effect size of g = -0.61 for the 25 mg dose, with the 10 mg dose not significantly outperforming control. That is a meaningful signal, but it is more modest than some headlines suggest.
The best one-line summary: pooled effects are in the moderate-to-large range,
but effect sizes in smaller or methodologically weaker studies are inflated.
The field is promising, not settled.
Why Psychedelics Are Not a Replacement for Standard Antidepressants
The evidence base is still early-phase.
Most trials are Phase 2, involve small samples, and have methodological limitations. Phase 3 trials are ongoing. Until those results are available, clinical caution is appropriate.
The infrastructure requirement is substantial.
Psilocybin therapy requires a 6-to-8-hour supervised session with trained therapists, preparation sessions, and post-session integration. Scaling this is logistically and economically challenging even where it is legal.
Contraindications are real and important.
The trials excluded patients with personal or first-degree family history of psychosis, mania, schizophrenia, and active suicidal intent. Psilocybin can precipitate or worsen psychosis in vulnerable individuals. A psychedelic experience in a medically unsupported setting, including the so-called bad trip, is not a minor inconvenience in a clinical population.
SSRIs and SNRIs attenuate psilocybin's effects.
Most trials require antidepressant taper before participation. This adds discontinuation risk and complexity. Some emerging work suggests psilocybin may retain some efficacy even with concurrent SSRIs, but this is not established practice.
It is not available in India.
Psilocybin is not approved for clinical use in India. Seeking it from unregulated sources carries risks of product contamination, unpredictable dosing, no psychological support, and significant legal consequences.
Can serotonergic psychedelics cause serotonin syndrome?
Serotonin syndrome is a potentially serious drug reaction caused by excess serotonergic activity, typically presenting as a triad of neuromuscular abnormalities (tremor, clonus, hyperreflexia), autonomic instability (tachycardia, hyperthermia, diaphoresis), and altered mental status. It ranges from mild and self-limiting to life-threatening. The question of whether psychedelics can trigger it is clinically relevant, particularly as more patients combine or consider combining these substances with prescribed antidepressants.
The answer depends on which psychedelic is involved.
Psilocybin or LSD combined with SSRIs/SNRIs: the theoretical risk exists because both act on serotonergic pathways, but in practice the combination does not appear to reliably cause serotonin syndrome. A 2025 review in Psychiatric Times noted that this combination is generally considered safe from a serotonin syndrome standpoint. This is consistent with the pharmacology: psilocybin and LSD are 5-HT2A agonists, not monoamine releasers or reuptake inhibitors, and serotonin syndrome requires excess synaptic serotonin rather than receptor agonism alone.
Ayahuasca combined with SSRIs or SNRIs: this is a different and genuinely dangerous combination. Ayahuasca contains beta-carboline MAOIs that inhibit monoamine oxidase A, the enzyme responsible for breaking down serotonin. When combined with SSRIs or SNRIs — which increase synaptic serotonin by blocking its reuptake — the result is a real risk of severe serotonin accumulation. Cases of serious serotonin syndrome have been documented. This is not a theoretical concern or a precaution to be exercised at individual discretion. It is a contraindication.
Why SSRIs reduce psychedelic effects: this is the second piece of the picture, and it matters practically. Chronic SSRI use downregulates 5-HT2A receptors through receptor internalisation. Since 5-HT2A agonism is psilocybin's primary mechanism of psychoactive effect, patients who have been on SSRIs for months or years find the psychedelic experience substantially blunted. Research from Imperial College London (Siva et al., 2024) confirmed this pharmacodynamic interaction. This is why psychedelic trials require a taper and washout period — typically 2–5 weeks, depending on the half-life of the specific antidepressant — before the session.
The clinical bottom line: do not stop an antidepressant without speaking to a psychiatrist first. Abrupt discontinuation carries real risks including discontinuation syndrome and mood relapse. The washout periods used in trials are supervised and planned, not unilateral decisions. If you are curious about whether psychedelic-assisted therapy might be relevant to your situation at any point in the future, that is a conversation to have in a consultation — not something to self-manage.
On the 'Hallucinations Cannot Be Medicine' Argument
A claim I encounter from clinicians without a psychopharmacology background is that hallucinations are by definition pathological and therefore no drug producing them can be therapeutic. This conflates the pharmacologically induced perceptual alteration of psilocybin with the psychopathological hallucinations of schizophrenia. The phenomenology, neurobiology, and clinical context are entirely different.
More importantly, the question of whether perceptual effects are necessary for antidepressant benefit is an active research question, not a settled one. Non-hallucinogenic 5-HT2A-related compounds show antidepressant-like effects in preclinical models. The hallucination-as-medicine framing is not the only model anyone is working with. The argument that 'it causes hallucinations therefore it cannot work does not engage with the pharmacology. It is worth retiring.
Frequently Asked Questions
Is MDMA in the same category as psilocybin for depression?
No, and conflating the two misrepresents the evidence. MDMA acts primarily through monoamine release rather than 5-HT2A agonism. Its strongest evidence is in PTSD (MAPS trials), not primary depression. Including MDMA in a claim about psychedelic antidepressants would overstate what the MDD-specific literature supports.
Why do some studies report effect sizes above 2?
Very large effect sizes (d > 1.5 or g > 1.5) in the psychedelic literature almost always come from small open-label studies, crossover designs, or cancer-related distress populations. Davis et al. 2021 reported d = 2.5 at 1 week in a small open-label study. These findings are real but not definitive. The larger, more controlled COMP360 trial showed g = -0.61. Reporting only the large effect sizes would misrepresent the field.
Can psilocybin be used while on antidepressants?
Most trials require antidepressant taper before participation, because SSRIs appear to attenuate psilocybin's 5-HT2A effects. A 2023 Neuropsychopharmacology study found psilocybin showed some antidepressant signal even in patients on concurrent SSRIs, but concurrent use is not standard practice and cannot be recommended outside a controlled trial setting.
Is psilocybin addictive?
Psilocybin does not produce physical dependence or activate dopamine reward pathways in the way addiction-associated substances do. There is no clinically recognised withdrawal syndrome. Psychological dependence is theoretically possible but has not been a feature of clinical trial populations.
Should I ask my psychiatrist about psychedelics?
Raising it in a consultation is reasonable if you are curious. A psychiatrist should engage with the question seriously and honestly. What you should not do is source psychedelics outside clinical settings. If you are struggling with depression that has not responded to treatment, a teleconsultation through ManoMitra can help you explore what evidence-based options exist for your situation.
Explore More on This Topic
Stopping Antidepressants Safely: What Is Deprescribing?
Antidepressants and Sexual Side Effects: What Patients Should Know
Conditions We Treat at ManoMitra
Dr. Anindo Mitra is a Consultant Psychiatrist at Athena Behavioural Health, Gurugram. He completed his MD in Psychiatry from JIPMER, Puducherry. His clinical focus includes evidence-based pharmacotherapy, deprescribing, and the neurobiology of psychiatric disorders. He writes at dranindomitra.com on mental health education for the Indian public.
This post is for educational purposes only and does not constitute individualised medical advice. If you have concerns about your mental health or treatment, please consult a qualified clinician.
